TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871365/0/en/TFF-Pharmaceuticals-Makes-Available-Phase-2-Data-from-Tacrolimus-Inhalation-Powder-TFF-TAC-for-the-Prevention-of-Lung-Transplant-Rejection-Presented-at-the-Recent-ISHLT-Annual-Meet.html

Data Now Available on Company Website Following 8-K Filing

Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.